The authors stated that there are no conflicts of interest regarding the publication of this article.
Clinical spectrum of MEN2A in a large family caused by the infrequent RET mutation Cys609Phe
Version of Record online: 23 JUL 2012
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Volume 83, Issue 4, pages 384–387, April 2013
How to Cite
Clinical spectrum of MEN2A in a large family caused by the infrequent RET mutation Cys609Phe., , , .
- Issue online: 12 MAR 2013
- Version of Record online: 23 JUL 2012
- Accepted manuscript online: 26 JUN 2012 01:28PM EST
- Manuscript Revised: 20 JUN 2012
- Manuscript Accepted: 20 JUN 2012
- Manuscript Received: 2 APR 2012
- RET proto-oncogene
Mutations in RET proto-oncogene cause multiple endocrine neoplasia 2A (MEN2A). Mutations in codons 609 and 611 are not frequent. We identified two MEN2A families with the Cys609Phe RET mutation, which turned out to be the same family. This mutation has been described a couple of times with no clinical details. We have characterized the clinical phenotype of this large kindred. A 54-year-old woman, with a medullary thyroid carcinoma (MTC), and a 33-year-old woman, who was operated on for an adrenal pheochromocytoma, were the index cases. 35 relatives were studied. Sixteen turned out to be carriers and 12 of them have been operated on. This family showed eight patients with C-cell hyperplasia, six patients affected by MTC and two showing pheochromocytoma. A papillary thyroid carcinoma was also found, together with the MTC, in one of the carriers. The phenotype in this large kindred is clearly of MEN2A. In carriers presenting the Cys609Phe mutation, the timing of the presentation of the syndrome is highly unpredictable. Therefore, a strict follow up of MTC must be carried out because of risk, and pheochromocytoma should not be ignored. These results reinforce the scarce data observed on this particular mutation.